Phaarmasia Intrinsic Value
PHRMASI Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹25.65 | ₹20.52 - ₹30.78 | -70.0% | EPS: ₹1.10, Sector P/E: 22x |
| Book Value Method | asset | ₹25.71 | ₹23.14 - ₹28.28 | -69.9% | Book Value/Share: ₹12.86, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹97.14 | ₹87.43 - ₹106.85 | +13.6% | Revenue/Share: ₹48.57, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹34.20 | ₹30.78 - ₹37.62 | -60.0% | EBITDA: ₹1.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹25.65 | ₹23.09 - ₹28.21 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹25.65 | ₹23.09 - ₹28.21 | -70.0% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹42.75 | ₹38.48 - ₹47.03 | -50.0% | ROE: 11.1%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹25.65 | ₹23.09 - ₹28.21 | -70.0% | EPS: ₹1.10, BVPS: ₹12.86 |
Want to compare with current market value? Check PHRMASI share price latest .
Valuation Comparison Chart
PHRMASI Intrinsic Value Analysis
What is the intrinsic value of PHRMASI?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Phaarmasia (PHRMASI) is ₹25.71 (median value). With the current market price of ₹85.50, this represents a -69.9% variance from our estimated fair value.
The valuation range spans from ₹25.65 to ₹97.14, indicating ₹25.65 - ₹97.14.
Is PHRMASI undervalued or overvalued?
Based on our multi-method analysis, Phaarmasia (PHRMASI) appears to be trading above calculated value by approximately 69.9%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Debt to Equity Ratio | 2.44 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 11.1% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | -4.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.55x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Phaarmasia
Additional stock information and data for PHRMASI
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |